Advertisement

Neurological Sciences

, Volume 32, Issue 5, pp 819–824 | Cite as

Bone mineral density in ambulatory patients with multiple sclerosis

  • Chrissa Sioka
  • Stylianos Papakonstantinou
  • Andreas Fotopoulos
  • Yiannis Alamanos
  • Athanasia Georgiou
  • Sofia Tsouli
  • Sygliti-Henrietta Pelidou
  • Athanassios P. Kyritsis
  • John Kalef-Ezra
Original Article

Abstract

Multiple sclerosis (MS) may be associated with reduced bone mass and higher frequency of osteoporosis. Femoral and spinal bone mineral density (BMD) in 70 ambulatory MS patients (46 females and 24 males) was compared with 100 sex-, age-, and BMI-matched control individuals. BMD was reduced in male patients (lumbar spine 0.976 ± 0.114 g/cm2 compared with 1.059 ± 0.147 g/cm2 in controls, p = 0.024, total hip 0.946 ± 0.136 g/cm2 compared to 1.036 ± 0.118 g/cm2 in controls, p = 0.008, femoral neck 0.812 ± 0.136 g/cm2 compared with 0.887 ± 0.135 g/cm2 in controls p = 0.042), and only in the total hip in female patients (0.88 ± 0.127 g/cm2 compared with 0.935 ± 0.112 g/cm2 in controls, p = 0.018). Multivariate analysis demonstrated that the predominantly affected site was the hip. MS patients exhibit increased frequency of low bone mass compared with controls. Further studies should assess the etiologic factors and employ appropriate therapies.

Keywords

Osteoporosis Osteopenia Bone mineral density (BMD) Multiple sclerosis (MS) 

References

  1. 1.
    Organization WH (2003) Prevention and management of osteoporosis. WHO Technical Report Series 921 GenevaGoogle Scholar
  2. 2.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929–1936. doi: 10.1016/S0140-6736(02)08761-5 PubMedCrossRefGoogle Scholar
  3. 3.
    Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43(6):1115–1121. doi: 10.1016/j.bone.2008.08.106 PubMedCrossRefGoogle Scholar
  4. 4.
    Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2 Suppl 1):4–9. doi: 10.1016/j.bone.2005.11.024 CrossRefGoogle Scholar
  5. 5.
    Hearn AP, Silber E (2010) Osteoporosis in multiple sclerosis. Mult Scler 16(9):735–739. doi: 10.1177/1352458510368985 Google Scholar
  6. 6.
    Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R (1997) Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 61(2):129–133PubMedCrossRefGoogle Scholar
  7. 7.
    Mojtahedi MC, Snook EM, Motl RW, Evans EM (2008) Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev 45(6):851–861PubMedCrossRefGoogle Scholar
  8. 8.
    Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y (2005) Vitamin d deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23(4):309–313. doi: 10.1007/s00774-005-0604-9 PubMedCrossRefGoogle Scholar
  9. 9.
    Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 9(6):600–604PubMedCrossRefGoogle Scholar
  10. 10.
    Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12(7):550–556. doi: 10.1111/j.1468-1331.2005.00988.x PubMedCrossRefGoogle Scholar
  11. 11.
    Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89(10):4923–4928. doi: 10.1210/jc.2004-0164 PubMedCrossRefGoogle Scholar
  12. 12.
    Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S (2009) The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 276(1–2):41–44. doi: 10.1016/j.jns.2008.08.031 PubMedCrossRefGoogle Scholar
  13. 13.
    Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V, Lindsay R (1998) Fracture history and bone loss in patients with ms. Neurology 51(4):1161–1165PubMedGoogle Scholar
  14. 14.
    Sioka C, Kyritsis AP, Fotopoulos A (2009) Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci 287(1–2):1–6. doi: 10.1016/j.jns.2009.09.012 Google Scholar
  15. 15.
    Kaptoge S, da Silva JA, Brixen K, Reid DM, Kroger H, Nielsen TL, Andersen M, Hagen C, Lorenc R, Boonen S, de Vernejoul MC, Stepan JJ, Adams J, Kaufman JM, Reeve J (2008) Geographical variation in dxa bone mineral density in young european men and women. Results from the network in europe on male osteoporosis (nemo) study. Bone 43(2):332–339. doi: 10.1016/j.bone.2008.04.001 PubMedCrossRefGoogle Scholar
  16. 16.
    Steffensen LH, Mellgren SI, Kampman MT (2010) Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 257(3):410–418. doi: 10.1007/s00415-009-5337-6 Google Scholar
  17. 17.
    Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M (2004) Risk of bone loss in men with multiple sclerosis. Mult Scler 10(2):170–175PubMedCrossRefGoogle Scholar
  18. 18.
    Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin d deficiency and reduced bone mass in multiple sclerosis. Neurology 44(9):1687–1692PubMedGoogle Scholar
  19. 19.
    Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH (1996) Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 53(8):753–757PubMedGoogle Scholar
  20. 20.
    Varoglu AO, Varoglu E, Bayraktar R, Aygul R, Ulvi H, Yildirim K (2010) The effect of interferon beta 1b on bone mineral density in multiple sclerosis patients. J Back Musculoskelet Rehabil 23(1):25–29. doi: 10.3233/BMR-2010-0244 Google Scholar
  21. 21.
    Cosman F, Nieves J, Herbert J, Shen V, Lindsay R (1994) High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 9(7):1097–1105PubMedCrossRefGoogle Scholar
  22. 22.
    Shabas D, Heffner M (2005) Multiple sclerosis management for low-income minorities. Mult Scler 11(6):635–640PubMedCrossRefGoogle Scholar
  23. 23.
    Schwarz S, Leweling H (2005) Multiple sclerosis and nutrition. Mult Scler 11(1):24–32PubMedCrossRefGoogle Scholar
  24. 24.
    Shabas D, Weinreb H (2000) Preventive healthcare in women with multiple sclerosis. J Womens Health Gend Based Med 9(4):389–395. doi: 10.1089/15246090050020709 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Chrissa Sioka
    • 1
  • Stylianos Papakonstantinou
    • 2
    • 3
  • Andreas Fotopoulos
    • 1
  • Yiannis Alamanos
    • 4
  • Athanasia Georgiou
    • 1
  • Sofia Tsouli
    • 2
  • Sygliti-Henrietta Pelidou
    • 2
    • 3
  • Athanassios P. Kyritsis
    • 2
    • 3
  • John Kalef-Ezra
    • 5
  1. 1.Department of Nuclear MedicineUniversity Hospital of IoanninaIoanninaGreece
  2. 2.Department of NeurologyUniversity Hospital of IoanninaIoanninaGreece
  3. 3.Neurosurgical Research InstituteUniversity of IoanninaIoanninaGreece
  4. 4.Department of Public HealthUniversity of PatrasPatrasGreece
  5. 5.Department of Medical PhysicsUniversity Hospital of IoanninaIoanninaGreece

Personalised recommendations